HIMS · Hims & Hers Health, Inc.

The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. “True health doesn’t happen in a vacuum. It’s the result of the data you gather, the insights you can access, and the daily choices you make,” said Dheerja Kaur, Chief Product Officer at Hims & Hers. “By leveraging our scale, we’re bringing health and wellness innovations like Prenuvo’s whole body MRI scans and Eight Sleep’s

Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims & Hers will become the largest global consumer health platform for access to more affordable, approved medications. The US weight loss landscape has transformed dramatically since Hims & Hers entered the market in 2023. Progress in the industry has made a broader range of FDA-approved GLP-1 treatments

Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. “More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leader in consumer health,” said Andrew Dudum, co-founder and CEO. “In 2025, we made it possible for more customers across the world to depend on us

Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company’s ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structured to preserve the financial flexibility of the company, ensuring continued control over balance sheet management and capital allocation. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and

The company will offer access to Galleri ® , an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear 1 . This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care. The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer. More than one in three people will develop cancer in their lifetime 2 , but many cancers can go undetected for longer than necessary especially before symptoms arise. While recommended screenings can catch breast, cervical, colorectal, prostate, and lung cancers

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company’s management team will be participating in the Morgan Stanley Technology, Media & Telecom Conference on March 2, 2026 in San Francisco. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the

New national spot “Rich People Live Longer” exposes America’s economically-driven health gap, declaring that access to life-changing care belongs to everyone Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, announced that it’s heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit “Sick of the System” ad, debuting a new national spot “ Rich People Live Longer ” with a simple message: the era of health as a luxury good is over, and proactive, life-changing care belongs to everyone. Next Sunday, Hims & Hers is stepping onto the nation’s biggest stage with an important wake up call. The new Big Game spot “Rich people live longer” makes one thing clear: proactive, life-changing care should belong to everyone. Through Hims & Hers, it does. The campaign centers on the uncomfortable truth that America’s healthcare is a tale of two systems: one elite, proactive tier for the wealthy, and a